Therapeutic potential of toleragens in the management of antiphospholipid syndrome

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Keith A CockerillMatthew D Linnik

Abstract

Autoantibodies to beta2-glycoprotein I (beta2GPI) are believed to be the primary cause of coagulation abnormalities in patients with antiphospholipid syndrome (APS). Clinical features include a range of life-threatening thrombotic events and microangiopathies affecting multiple organ systems. Current standard of care relies on long-term, high-intensity anticoagulation and is associated with a high risk for serious bleeding events. The relation between autoantibodies and the pathophysiology of APS is not clearly understood, but numerous in vitro studies have characterized the effects of antiphospholipid autoantibodies on various components of the coagulation cascade, including tissue factor and the protein C pathway. The fine specificity of autoantibodies to beta2GPI is a subject of considerable debate; however, a body of evidence may offer resolution by integrating concepts of antibody affinity and assay sensitivity with carefully designed molecular studies. An investigational new therapy for APS is based on the approach that pathogenic antibodies may be reduced via depletion of circulating autoantibodies and induction of immune tolerance at the B-cell level. Preliminary results from a phase I/II clinical trial with LJP 1082, a...Continue Reading

References

Dec 15, 1992·Annals of Internal Medicine·K S GinsburgM J Stampfer
Sep 1, 1992·Thrombosis Research·M UdvardyK Rak
Aug 15, 1992·Annals of Internal Medicine·M H Rosove, P M Brewer
Jul 21, 1990·Lancet
Apr 1, 1991·Neurology·D C HessH A Rountree
Sep 1, 1990·British Journal of Haematology·R G MaliaF E Preston
Jun 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·H P McNeilS A Krilis
Nov 10, 1989·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·R OmdalW Hinderaker
Jul 12, 1986·Lancet
May 1, 1986·The New England Journal of Medicine·R CariouJ Caen
Jan 1, 1987·Scandinavian Journal of Rheumatology·R H DerksenL Kater
Mar 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·J E HuntS A Krilis
Oct 1, 1995·Internal Medicine·T Koike, A Tsutsumi
Oct 1, 1996·Human Reproduction·J BalaschJ A Vanrell
Nov 1, 1996·Internal Medicine·T Kunieda
Jan 9, 1998·Journal of Reproductive Immunology·W H Kutteh
Aug 26, 1998·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·V EschwègeD Meyer
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·G M IversonD M Marquis
Apr 8, 1999·Clinical and Experimental Immunology·L W ChamleyP M Johnson
Nov 11, 1999·Neurological Research·J ZieliñskaA Czlonkowska
Jun 9, 2000·Clinical and Experimental Immunology·J G Hanly, S A Smith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.